Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
AssigneeGenethon
InventorsOtto-Wilhelm Merten, Martin Marek, Monique Van Oers
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the production of biopharmaceuticals implementing a baculovirus-based system. These methods advantageously allow the production of biopharmaceuticals with a reduced number of or without contaminating baculoviral virions.
Claims21
A method for the production of a biopharmaceutical product, comprising:
- (a) infecting a biopharmaceutical-producing insect cell with at least one baculovirus, said at least one baculovirus comprising a genome coding for said biopharmaceutical product, and (b) maintaining the biopharmaceutical-producing insect cell under conditions such that the biopharmaceutical product is produced, wherein the genome of said at least one baculovirus is deficient for the p6.9 gene and, optionally, deficient for at least one gene selected from vp80, vp1054 and vp39, or wherein said biopharmaceutical-producing insect cell comprises an expression control system allowing the inactivation of the p6.9 gene and, optionally, inactivation at least one gene selected from vp80, vp1054 and vp39.
A bacmid comprising a baculoviral genome, wherein said genome is deficient for the p6.9 gene.
A recombinant baculovirus vector, wherein the genome of said baculovirus vector is deficient for the p6.9 gene.
An insect cell infected with a recombinant baculovirus vector comprising a genome which is deficient for the p6.9 gene.
A method for the production of a baculovirus deficient for the p6.9 gene, comprising the step of transfecting an insect cell comprising an expression cassette coding for the p6.9 gene with a bacmid comprising a baculoviral genome, wherein said genome is deficient for the p6.9 gene.
Dependencies are inferred from the claim text.